Evaluation the impact of Helicobacter pylori eradication on motor and non-motor symptoms and quality of life in patients with Parkinsons disease.

Investigator Initiated Study0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. PD patients diagnosed based on UKPDS brain bank criteria and Hoehn and Yahr score of 2-4.
•2. Patients on stable drug therapy for at least 30 days, with wearing off phenomenon
•existing between L-Dopa dosing (mean daily off time >=3 hours)
•3. Normal cognition (Montreal cognitive assessment score >25)
•4. Patient who are willing to give consent for participation.

•1. Ongoing symptoms of abdominal pain, unexplained nausea and vomiting, or GI
•2. History of HP associated conditions - gastric carcinoma, peptic ulcer disease,
•duodenal ulcer, or other gastric or duodenal conditions.
•3. Patients with a history of past gastric surgery.
•4. History of prior neurosurgery for PD.
•5. History of stomach cancer in the family.
•6. Prior HP eradication treatment or diagnosis.
•7. Recent use of PPIs, amoxicillin, clarithromycin, metronidazole, colloidal bismuth sub
•citrate (CBS) with past 4 weeks.
•8. Allergy or sensitivity to HP eradication treatment regimen component drugs.
•9. Use of drugs that affect GI motility such as domperidone, metoclopramide
•10. Inability to participate/tolerate the morning testing during the study in an off state.
•11. Pregnancy.
•12. Parkinson- plus syndrome e.g. MSA, PSP, corticobasal degeneration (CBD), or Lewy
•body dementia.
•13. Secondary causes of parkinsonism e.g. vascular parkinsonism, major head injury, past
•h/o encephalitis, neuroleptic treatment at onset of symptoms, h/o psychiatric disease,
•reversible cause of parkinsonism.
•14. Patients refuse to participate in the study and not willing to give consent.

发起方

Investigator Initiated Study